Publications by authors named "Yoichi Imai"

Claim this Profile
L
Long-term prognosis of pure membranous lupus nephritis: a comparison with proliferative lupus nephritis in Japan.
Hidekazu Ikeuchi, Yoichi Imai, Shoichi Maruyama, Hitoshi Sugiyama, Hiroshi Sato

Clin Exp Nephrol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells.
Fumi Nakamura, Yuka Nakamura, Ko Sasaki, Ieharu Yamazaki, Yoichi Imai

Leuk Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.
Junya Makiyama, Nobuhiro Ohno, Koji Jimbo, Toyotaka Kawamata, Kazuaki Yokoyama, Yoichi Imai

Int J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CML Patient Carrying BCR::ABL1 Splicing Variants Did Not Experience Blast Crisis for 15 Years without Responding to Various TKIs.
Fumi Nakamura, Ko Sasaki, Yasuhito Nannya, Hisako Iso, Yuko Nakamura, Yoichi Imai

Intern Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A whole gamma imaging prototype for higher quantitative imaging ofZr-labeled antibodies in a tumor mouse model.
Sodai Takyu, Hideaki Tashima, Miwako Takahashi, Eiji Yoshida, Hidekatsu Wakizaka, Yoichi Imai

Phys Med Biol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Preface].
Yoichi Imai

Rinsho Ketsueki· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.
Yu-Hsuan Chang, Keita Yamamoto, Takeshi Fujino, Teh-Wei Wang, Emi Sugimoto, Yoichi Imai

Cell Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
Yuta Kaito, Yoichi Imai

Int J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel treatment strategies for hematological malignancies in the immunotherapy era.
Yoichi Imai

Int J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
Yuta Kaito, Emi Sugimoto, Fumi Nakamura, Yutaka Tsukune, Makoto Sasaki, Yoichi Imai

Haematologica· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.
Emi Sugimoto, Jingmei Li, Yasutaka Hayashi, Kohei Iida, Shuhei Asada, Yoichi Imai

Commun Biol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).
Fumi Nakamura, Sachiko Seo, Yasuhito Nannya, Rika Ayabe, Wataru Takahashi, Yoichi Imai

Int J Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Future PET Imaging for Multiple Myeloma.
Mariko Ishibashi, Miwako Takahashi, Taiga Yamaya, Yoichi Imai

Life (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma.
Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai

Exp Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Yoichi Imai

Mol Cells· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Mechanism of action and clinical results of immunotherapy for multiple myeloma].
Yoichi Imai

Rinsho Ketsueki· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Tatsuya Masuda, Shintaro Maeda, Sae Shimada, Naoya Sakuramoto, Ken Morita, Yoichi Imai

Cancer Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD155 and CD112 as possible therapeutic targets of inhibitors for acute myeloid leukemia.
Yuta Kaito, Mitsuhito Hirano, Muneyoshi Futami, Masanori Nojima, Hideto Tamura, Yoichi Imai

Oncol Lett· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation.
Yuta Kaito, Takaaki Konuma, Maki Monna-Oiwa, Seiko Kato, Masamichi Isobe, Yoichi Imai

Int J Lab Hematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.
Hiroshi Yasui, Masayuki Kobayashi, Kota Sato, Kanya Kondoh, Tadao Ishida, Yoichi Imai

Int J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thiamine Deficiency and Neurological Symptoms in Patients with Hematological Cancer Receiving Chemotherapy: A Retrospective Analysis.
Yohei Iimura, Shohei Andoh, Toyotaka Kawamata, Aki Sato, Kazuaki Yokoyama, Yoichi Imai

J Neurosci Rural Pract· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between thiamine decrease and neuropsychiatric symptoms in gastrointestinal and hematological cancer patients receiving chemotherapy.
Yohei Iimura, Tomohiro Kurokawa, Shohei Andoh, Yoshiaki Kanemoto, Toyotaka Kawamata, Yoichi Imai

Biomed Pharmacother· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RUNX inhibitor suppresses graft-versus-host disease through targeting axis.
Hirohito Kubota, Tatsuya Masuda, Mina Noura, Kana Furuichi, Hidemasa Matsuo, Yoichi Imai

EJHaem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of activated integrin β7 in multiple myeloma patients.
Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, Masaki Ri, Yasuyuki Nagata, Yoichi Imai

Int J Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Current status and future prospects of immunotherapy for multiple myeloma].
Yoichi Imai

Rinsho Ketsueki· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis